125 related articles for article (PubMed ID: 30392342)
1. [Clinical observation of thyroid-related adverse events induced by anti-PD-1 antibody SHR-1210 in patients with advanced solid tumor].
Qi L; Mo HN; Chen XL; Wang X; Wu DW; Lan B; Li Q; Wang XY; Xu JP; Yang Q; Xu BH; Huang J
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):772-775. PubMed ID: 30392342
[No Abstract] [Full Text] [Related]
2. [The clinical reports on adrenal insufficiency of patients with advanced solid tumors accepting anti-PD-1 antibody, SHR-1210 therapy].
Tang JL; Huang J; Wang X; Chen XL; Li Q; Mo HN; Wu DW; Lan B; Xu BH
Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):466-470. PubMed ID: 31216835
[No Abstract] [Full Text] [Related]
3. BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION.
Pollack RM; Kagan M; Lotem M; Dresner-Pollak R
Endocr Pract; 2019 Aug; 25(8):824-829. PubMed ID: 31013164
[No Abstract] [Full Text] [Related]
4. Nivolumab-induced thyroid dysfunction.
Tanaka R; Fujisawa Y; Maruyama H; Nakamura Y; Yoshino K; Ohtsuka M; Fujimoto M
Jpn J Clin Oncol; 2016 Jun; 46(6):575-9. PubMed ID: 27012985
[TBL] [Abstract][Full Text] [Related]
5. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
Osorio JC; Ni A; Chaft JE; Pollina R; Kasler MK; Stephens D; Rodriguez C; Cambridge L; Rizvi H; Wolchok JD; Merghoub T; Rudin CM; Fish S; Hellmann MD
Ann Oncol; 2017 Mar; 28(3):583-589. PubMed ID: 27998967
[TBL] [Abstract][Full Text] [Related]
6. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
7. Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy.
Luongo C; Morra R; Gambale C; Porcelli T; Sessa F; Matano E; Damiano V; Klain M; Schlumberger M; Salvatore D
J Endocrinol Invest; 2021 Sep; 44(9):1927-1933. PubMed ID: 33576954
[TBL] [Abstract][Full Text] [Related]
8. Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: a pilot study.
Raterman HG; Jamnitski A; Lems WF; Voskuyl AE; Dijkmans BA; Bos WH; Simsek S; Lips P; van de Stadt RJ; de Koning MH; Nurmohamed MT
J Rheumatol; 2011 Feb; 38(2):247-51. PubMed ID: 21078720
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.
Yoon JH; Hong AR; Kim HK; Kang HC
Endocrinol Metab (Seoul); 2021 Apr; 36(2):413-423. PubMed ID: 33820396
[TBL] [Abstract][Full Text] [Related]
10. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
[TBL] [Abstract][Full Text] [Related]
11. Associations between metabolic syndrome, serum thyrotropin, and thyroid antibodies status in postmenopausal women, and the role of interleukin-6.
Siemińska L; Wojciechowska C; Walczak K; Borowski A; Marek B; Nowak M; Kajdaniuk D; Foltyn W; Kos-Kudła B
Endokrynol Pol; 2015; 66(5):394-403. PubMed ID: 26457493
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):437-444. PubMed ID: 29652599
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine.
Koulouri O; Auldin MA; Agarwal R; Kieffer V; Robertson C; Falconer Smith J; Levy MJ; Howlett TA
Clin Endocrinol (Oxf); 2011 Jun; 74(6):744-9. PubMed ID: 21521256
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer.
Zhang X; Wu Y; Lv J; Li X; Ma L; Nong J; Zhang H; Qin N; Zhang Q; Shi G; Yang X; Wang J; Zhang S
Interdiscip Sci; 2019 Jun; 11(2):287-291. PubMed ID: 31187431
[TBL] [Abstract][Full Text] [Related]
15. Change in serum thyroid-stimulating hormone concentration in response to administration of thyrotropin-releasing hormone to healthy dogs, hypothyroid dogs, and euthyroid dogs with concurrent disease.
Scott-Moncrieff JC; Nelson RW
J Am Vet Med Assoc; 1998 Nov; 213(10):1435-8. PubMed ID: 9828939
[TBL] [Abstract][Full Text] [Related]
16. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism.
Shimon I; Cohen O; Lubetsky A; Olchovsky D
Thyroid; 2002 Sep; 12(9):823-7. PubMed ID: 12481949
[TBL] [Abstract][Full Text] [Related]
17. Measurement of serum total thyroxine, triiodothyronine, free thyroxine, and thyrotropin concentrations for diagnosis of hypothyroidism in dogs.
Peterson ME; Melián C; Nichols R
J Am Vet Med Assoc; 1997 Dec; 211(11):1396-402. PubMed ID: 9394888
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone/insulin-like growth factor axis in patients with subclinical thyroid dysfunction.
Akin F; Yaylali GF; Turgut S; Kaptanoglu B
Growth Horm IGF Res; 2009 Jun; 19(3):252-5. PubMed ID: 19111490
[TBL] [Abstract][Full Text] [Related]
19. Screening of geriatric patients for thyroid dysfunction with thyrotropin-releasing-hormone test, sensitive thyrotropin and free thyroxine estimation.
Szabolcs I; Ploenes C; Bernard W; Herrmann J
Horm Metab Res; 1990 May; 22(5):298-302. PubMed ID: 2112111
[TBL] [Abstract][Full Text] [Related]
20. Childhood maltreatment is associated with increased risk of subclinical hypothyroidism in pregnancy.
Moog NK; Heim CM; Entringer S; Kathmann N; Wadhwa PD; Buss C
Psychoneuroendocrinology; 2017 Oct; 84():190-196. PubMed ID: 28755549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
